Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Inks Prostate Cancer Test Coverage Deal With Priority Health

NEW YORK (GenomeWeb) – MDxHealth today announced that its ConfirmMDx test for prostate cancer will now be covered by Michigan-based health plan Priority Health for all of its nearly 720,000 members.

Additional terms of the deal were not disclosed.

ConfirmMDx for Prostate Cancer detects the methylation status of biomarkers associated with the cancer development process, identifying patients who many not need a repeat biopsy following a negative result. Earlier this year, the test was included in the US 2016 National Comprehensive Cancer Network (NCCN) Guidelines for prostate cancer screening.

"With the recent inclusion of ConfirmMDx in the NCCN clinical guidelines, we are gaining more momentum with commercial payors," CEO Jan Groen said in a statement. "Our coverage for ConfirmMDx continues to grow, and the test is now covered by policies serving more than 50 percent of US at-risk males between the age of 50 and 74."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.